Oxurion NV Asset Resilience Ratio
Oxurion NV asset resilience ratio. Oxurion NV (OXUR) has an Asset Resilience Ratio of 0.76% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Oxurion NV (OXUR) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Oxurion NV (2006–2023)
Asset resilience ratio of Oxurion NV from 2006 to 2023. This chart shows how Oxurion NV's Asset Resilience Ratio has changed over time. Read OXUR liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Oxurion NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Oxurion NV (OXUR) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €50.00K | 0.76% |
| Total Liquid Assets | €50.00K | 0.76% |
Asset Resilience Insights
- Limited Liquidity: Oxurion NV maintains only 0.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Oxurion NV Industry Peers by Asset Resilience Ratio
Compare Oxurion NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Oxurion NV Asset Resilience Ratio by Year (2006–2023)
Oxurion NV asset resilience ratio by year from 2006 to 2023. The table below shows the annual Asset Resilience Ratio data for Oxurion NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.76% | €50.00K ≈ $58.46K |
€6.55 Million ≈ $7.66 Million |
-0.03pp |
| 2022-12-31 | 0.79% | €95.00K ≈ $111.06K |
€11.99 Million ≈ $14.02 Million |
-0.52pp |
| 2021-12-31 | 1.31% | €247.00K ≈ $288.77K |
€18.88 Million ≈ $22.07 Million |
+0.47pp |
| 2020-12-31 | 0.84% | €288.00K ≈ $336.70K |
€34.28 Million ≈ $40.08 Million |
-15.22pp |
| 2019-12-31 | 16.06% | €10.44 Million ≈ $12.21 Million |
€65.03 Million ≈ $76.03 Million |
-1.77pp |
| 2018-12-31 | 17.83% | €20.48 Million ≈ $23.94 Million |
€114.86 Million ≈ $134.29 Million |
-15.12pp |
| 2017-12-31 | 32.94% | €49.55 Million ≈ $57.94 Million |
€150.44 Million ≈ $175.88 Million |
+15.00pp |
| 2016-12-31 | 17.94% | €21.82 Million ≈ $25.51 Million |
€121.64 Million ≈ $142.21 Million |
+13.44pp |
| 2015-12-31 | 4.50% | €8.04 Million ≈ $9.40 Million |
€178.95 Million ≈ $209.21 Million |
+2.75pp |
| 2014-12-31 | 1.75% | €3.85 Million ≈ $4.50 Million |
€220.71 Million ≈ $258.04 Million |
-1.13pp |
| 2013-12-31 | 2.87% | €7.79 Million ≈ $9.11 Million |
€271.15 Million ≈ $317.01 Million |
-0.82pp |
| 2012-12-31 | 3.69% | €8.83 Million ≈ $10.33 Million |
€239.17 Million ≈ $279.62 Million |
-13.99pp |
| 2011-12-31 | 17.69% | €22.83 Million ≈ $26.69 Million |
€129.09 Million ≈ $150.92 Million |
+1.39pp |
| 2010-12-31 | 16.29% | €23.29 Million ≈ $27.23 Million |
€142.94 Million ≈ $167.11 Million |
+15.56pp |
| 2009-12-31 | 0.73% | €742.00K ≈ $867.48K |
€101.22 Million ≈ $118.34 Million |
-41.77pp |
| 2008-12-31 | 42.51% | €28.57 Million ≈ $33.40 Million |
€67.20 Million ≈ $78.57 Million |
+29.60pp |
| 2007-12-31 | 12.90% | €6.71 Million ≈ $7.84 Million |
€52.00 Million ≈ $60.79 Million |
+10.98pp |
| 2006-12-31 | 1.92% | €718.00K ≈ $839.42K |
€37.33 Million ≈ $43.65 Million |
-- |
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more